Filed under Mapping, Population by Sequenom News Release on July 27, 2009 at 5:32 pm
no comments
--New System Delivers Fast, Efficient, Cost-Effective Solution for Clinical Research SAN DIEGO, July 27, 2009 /PRNewswire-FirstCall via COMTEX/ -- SEQUENOM, Inc. (Nasdaq: SQNM) today announced the launch of the MassARRAY(R) Compact 96 system.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)
This generation of the MassARRAY system now addresses the needs of lower throughput laboratories. The combination of features of the new MassARRAY Compact 96 system - accuracy, sensitivity, and now the ability to cost-effectively run fewer samples - make this an ideal system for use in basic and clinical laboratories.
With the addition of the MassARRAY Compact 96 system SEQUENOM n...
Filed under Cancer, Diagnostics by Sequenom News Release on July 13, 2009 at 5:32 pm
no comments
New Study Uncovers Significant Proportion of Potential False Negatives in
Widely Used HPV DNA Test which could lead to Cervical Cancer
SAN DIEGO and ANN ARBOR, Mich., July 13 /PRNewswire-FirstCall/ -- Results
from a study published by the University of Michigan have shown that as many
as 15% of women in the study group determined to be negative for the presence
of human papillomavirus (HPV) in the cervix, via the most commonly used test
for HPV DNA, may actually be infected with the virus at clinically relevant
viral loads. PCR-MS detected the presence of high-risk HPV in nearly half
(46.7%) of women who tested negative by the Hybrid Capture 2 (HC2) test, whi...
Filed under Industry news, Patents by Sequenom News Release on January 26, 2009 at 6:06 pm
no comments
SensiGen Proprietary AttoSense(TM) Assays for HPV, Cervical Cancer and Other Diseases Complement Sequenom's Growing Noninvasive Test Portfolio
SAN DIEGO & ANN ARBOR, Mich.--(BUSINESS WIRE)--Jan. 26, 2009--Sequenom, Inc. (NASDAQ:SQNM) announced an agreement to acquire the
complete AttoSense(TM) portfolio of tests along with certain other assets
from privately held biotechnology company SensiGen LLC. SensiGen has
been developing advanced gene-based molecular tests with diagnostic
potential under a partnership agreement with Sequenom. The acquisition
includes analytically validated, ultra-sensitive and ultra-specific
tests for detection and monitor...
Filed under Cancer, Core facilities by Sequenom News Release on January 14, 2009 at 6:01 am
no comments
SAN DIEGO--(BUSINESS WIRE)--Jan. 14, 2009--Sequenom, Inc. (NASDAQ:SQNM) announced that it intends to make an
exchange offer to acquire all of the outstanding shares of common stock
of EXACT Sciences Corporation (NASDAQ:EXAS) in an all-stock transaction
valued at approximately $41 million. Under the terms of the proposal,
each share of EXACT Sciences would be exchanged for $1.50 in Sequenom
common stock. This consideration would be subject to a floating exchange
rate within a 15% collar, in which the price of Sequenom's common stock
is between $20.74 and $28.06 per share. The acquisition of EXACT
Sciences, a pioneer in noninvasive st...
